Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression

NCT03417882 is registered in ClinicalTrials.gov with BrightPath Biotherapeutics as lead sponsor.

NCT NCT03417882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03417882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Lead sponsor
BrightPath Biotherapeutics
Phase
Phase 2
Overall status
Terminated
Start date
January 3, 2019
Completion date
December 5, 2022
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc